Literature DB >> 30686773

Influenza Vaccination Documentation Rates During the First Year After Diagnosis of Diffuse Large B Cell Lymphoma.

Andres Chang1, Jackelyn B Payne2, Pamela B Allen2, Jean L Koff2, Rafi Ahmed3, Christopher R Flowers2, Robert A Bednarczyk4.   

Abstract

INTRODUCTION: Influenza infection causes significant morbidity and mortality in patients with cancer, and annual influenza vaccination for individuals with cancer is recommended. We sought to examine the documentation rate of influenza vaccine administration, refusal, or counseling in the first year after diagnosis of diffuse large B cell lymphoma (DLBCL) for patients across 3 hospitals in 2 health care systems. PATIENTS AND METHODS: Documentation of vaccine administration, refusal, or counseling by physicians, advanced practice providers, or nursing staff during the first period of influenza vaccine availability after diagnosis (August to April) was assessed in medical records of patients diagnosed with DLBCL between February 2015 and October 2017 who presented to Emory St. Joseph Hospital (community hospital), Winship Cancer Institute of Emory University (academic medical center), or Grady Memorial Hospital (county hospital).
RESULTS: Of the 57% (61/107) of newly diagnosed patients with DLBCL who had vaccine-related documentation, 43% refused vaccination. Counseling was not documented for any patient. Inpatient nursing performed 75% of all documentation. Primary oncologists documented vaccination in 4% of all cases.
CONCLUSION: Despite the limited immunization documentation and high refusal rates observed in this study, the influenza vaccine refusal rate was lower than the average for the United States, the state of Georgia, and the previous studies of patients with cancer. Although routine outpatient vaccination occurs, improvements in screening, strategies for sharing patient vaccine-related information, and counseling of patients who refuse the vaccine are needed. Further work is also needed to determine the effectiveness of influenza vaccination in patients receiving anti-cancer therapy.
Copyright © 2018 Elsevier Inc. All rights reserved.

Entities:  

Keywords:  DLBCL; Flu vaccine; Influenza vaccine; Non-Hodgkin lymphoma; Vaccine screening

Mesh:

Substances:

Year:  2019        PMID: 30686773      PMCID: PMC6513688          DOI: 10.1016/j.clml.2018.12.018

Source DB:  PubMed          Journal:  Clin Lymphoma Myeloma Leuk        ISSN: 2152-2669


  14 in total

1.  Impaired response to influenza vaccine associated with persistent memory B cell depletion in non-Hodgkin's lymphoma patients treated with rituximab-containing regimens.

Authors:  Davide Bedognetti; Gabriele Zoppoli; Carlotta Massucco; Elisa Zanardi; Simonetta Zupo; Andrea Bruzzone; Mario Roberto Sertoli; Enrico Balleari; Omar Racchi; Marco Messina; Graziano Caltabiano; Giancarlo Icardi; Paolo Durando; Francesco M Marincola; Francesco Boccardo; Manlio Ferrarini; Filippo Ansaldi; Andrea De Maria
Journal:  J Immunol       Date:  2011-04-15       Impact factor: 5.422

2.  Robust memory responses against influenza vaccination in pemphigus patients previously treated with rituximab.

Authors:  Alice Cho; Bridget Bradley; Robert Kauffman; Lalita Priyamvada; Yevgeniy Kovalenkov; Ron Feldman; Jens Wrammert
Journal:  JCI Insight       Date:  2017-06-15

3.  Seasonal and pandemic (A/H1N1 2009) MF-59-adjuvanted influenza vaccines in complete remission non-Hodgkin lymphoma patients previously treated with rituximab containing regimens.

Authors:  Davide Bedognetti; Filippo Ansaldi; Elisa Zanardi; Paolo Durando; Mario Roberto Sertoli; Carlotta Massucco; Enrico Balleari; Omar Racchi; Gabriele Zoppoli; Andrea Orsi; Cristiano Alicino; Giancarlo Icardi; Francesco M Marincola; Simonetta Zupo; Manlio Ferrarini; Andrea De Maria
Journal:  Blood       Date:  2012-08-30       Impact factor: 22.113

4.  Rituximab blocks protective serologic response to influenza A (H1N1) 2009 vaccination in lymphoma patients during or within 6 months after treatment.

Authors:  Olav Erich Yri; Dag Torfoss; Olav Hungnes; Anne Tierens; Kristian Waalen; Tone Nordøy; Susanne Dudman; Anette Kilander; Karin Fahl Wader; Bjørn Ostenstad; Roald Ekanger; Peter Meyer; Arne Kolstad
Journal:  Blood       Date:  2011-11-04       Impact factor: 22.113

5.  The Cost of Interventions to Increase Influenza Vaccination: A Systematic Review.

Authors:  Laura J Anderson; Paul Shekelle; Emmett Keeler; Lori Uscher-Pines; Roberta Shanman; Sally Morton; Gursel Aliyev; Teryl K Nuckols
Journal:  Am J Prev Med       Date:  2018-01-18       Impact factor: 5.043

6.  The pandemic H1N1 influenza vaccine results in low rates of seroconversion for patients with hematological malignancies.

Authors:  Katherine Monkman; James Mahony; Alejandro Lazo-Langner; Benjamin H Chin-Yee; Leonard A Minuk
Journal:  Leuk Lymphoma       Date:  2011-06-12

7.  Influenza Vaccination Coverage Among People With High-Risk Conditions in the U.S.

Authors:  Alissa C O'Halloran; Peng-Jun Lu; Walter W Williams; Carolyn B Bridges; James A Singleton
Journal:  Am J Prev Med       Date:  2015-08-01       Impact factor: 5.043

Review 8.  Increasing Coverage of Appropriate Vaccinations: A Community Guide Systematic Economic Review.

Authors:  Verughese Jacob; Sajal K Chattopadhyay; David P Hopkins; Jennifer Murphy Morgan; Adesola A Pitan; John M Clymer
Journal:  Am J Prev Med       Date:  2016-02-01       Impact factor: 5.043

9.  Prevention and Control of Seasonal Influenza with Vaccines: Recommendations of the Advisory Committee on Immunization Practices - United States, 2017-18 Influenza Season.

Authors:  Lisa A Grohskopf; Leslie Z Sokolow; Karen R Broder; Emmanuel B Walter; Joseph S Bresee; Alicia M Fry; Daniel B Jernigan
Journal:  MMWR Recomm Rep       Date:  2017-08-25

10.  Practice-, Provider-, and Patient-level interventions to improve preventive care: Development of the P3 Model.

Authors:  Robert A Bednarczyk; Allison Chamberlain; Kara Mathewson; Daniel A Salmon; Saad B Omer
Journal:  Prev Med Rep       Date:  2018-06-18
View more
  2 in total

1.  Using Behavioral Science to Address COVID-19 Vaccine Hesitancy Among Cancer Survivors: Communication Strategies and Research Opportunities.

Authors:  Robin C Vanderpool; Anna Gaysynsky; Wen-Ying Sylvia Chou; Emily S Tonorezos
Journal:  J Behav Med       Date:  2022-03-19

2.  Impaired Immune Health in Survivors of Diffuse Large B-Cell Lymphoma.

Authors:  Tanaya Shree; Qian Li; Sally L Glaser; Ann Brunson; Holden T Maecker; Robert W Haile; Ronald Levy; Theresa H M Keegan
Journal:  J Clin Oncol       Date:  2020-02-21       Impact factor: 50.717

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.